QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
None
|
N/A
|
N/A |
Large accelerated filer ☐
|
Accelerated filer ☐
|
|
|
Smaller reporting company
|
|
Emerging growth company
|
|
Page
|
|
PART I – FINANCIAL INFORMATION
|
||
|
|
|
Item 1.
|
4
|
|
|
|
|
|
4
|
|
|
|
|
|
5
|
|
|
|
|
|
6
|
|
|
|
|
|
7
|
|
|
|
|
|
8
|
|
|
|
|
Item 2.
|
15
|
|
|
|
|
Item 3.
|
18
|
|
|
|
|
Item 4.
|
18
|
|
|
|
|
PART II – OTHER INFORMATION
|
||
|
|
|
Item 1.
|
20
|
|
|
|
|
Item 1A.
|
20
|
|
|
|
|
Item 2.
|
20
|
|
|
|
|
Item 3.
|
20
|
|
|
|
|
Item 4.
|
|
|
|
|
|
Item 5.
|
20
|
|
|
|
|
Item 6.
|
21
|
|
|
|
|
|
23
|
March 31, 2023
|
December 31, 2022
|
|||||||
ASSETS
|
||||||||
Current Assets:
|
||||||||
Cash
|
$
|
|
$
|
|
||||
Accounts receivable, net of allowance of $
|
|
|
||||||
Inventory
|
|
|
||||||
Prepaid expenses and other current assets
|
|
|
||||||
Total Current Assets
|
|
|
||||||
Property, Equipment and Other, net
|
|
|
||||||
Intangible Assets, net
|
|
|
||||||
Goodwill
|
|
|
||||||
Total Non-current Assets |
||||||||
Total Assets
|
$
|
|
$
|
|
||||
LIABILITIES
|
||||||||
Current Liabilities:
|
||||||||
Senior secured debt, in default
|
$
|
|
$
|
|
||||
Convertible promissory notes payable
|
||||||||
Convertible promissory notes payable, related parties
|
||||||||
Accounts payable
|
|
|
||||||
Accrued expenses
|
|
|
||||||
Due under factoring ageement
|
||||||||
Warrant liability
|
|
|
||||||
Accrued interest
|
|
|
||||||
Accrued interest, related parties
|
|
|
||||||
Current portion of contract liabilities
|
|
|
||||||
Other
|
|
|
||||||
Total Current Liabilities
|
|
|
||||||
Non-current Liabilities
|
||||||||
Lease liabilities
|
|
|
||||||
Contract liabilities
|
|
|
||||||
Deferred tax liability
|
|
|
||||||
Total Non-currrent Liabilities
|
|
|
||||||
Total Liabilities
|
$ |
|
$ |
|
||||
Commitments and Contingencies (Footnote 11)
|
||||||||
STOCKHOLDERS’ DEFICIT
|
||||||||
Preferred Stock, par value $
|
$ |
|
$ |
|
||||
Common Stock, par value $
|
|
|
||||||
Additional Paid-in Capital
|
|
|
||||||
Accumulated Deficit
|
(
|
)
|
(
|
)
|
||||
Accumulated Other Comprehensive Loss
|
(
|
)
|
(
|
)
|
||||
Total Stockholders’ Deficit
|
(
|
)
|
(
|
)
|
||||
Total Liabilities and Stockholders’ Deficit
|
$
|
|
$
|
|
Three Months Ended March 31,
|
||||||||
2023
|
2022
|
|||||||
Revenue
|
$
|
|
$
|
|
||||
Cost of Revenues
|
|
|
||||||
Gross Margin
|
|
|
||||||
Operating Expenses:
|
||||||||
General and administrative
|
|
|
||||||
Selling and marketing
|
|
|
||||||
Research and development
|
|
|
||||||
Depreciation and amortization
|
||||||||
Total Operating Expenses
|
|
|
||||||
Operating Loss
|
(
|
)
|
(
|
)
|
||||
Other Income (Expense):
|
||||||||
Interest expense
|
(
|
)
|
(
|
)
|
||||
Interest expense, related party
|
(
|
)
|
(
|
)
|
||||
Change in fair value of derivative liabilities
|
(
|
)
|
|
|||||
Loss on issuance of debt
|
( |
) | ||||||
Other expense |
( |
) | ||||||
Gain / (loss) on foreign currency exchange
|
|
(
|
)
|
|||||
Total Other Expense
|
(
|
)
|
(
|
)
|
||||
Net Loss before Income Taxes
|
(
|
)
|
(
|
)
|
||||
Provision for Income Taxes
|
|
|
||||||
Net Loss
|
(
|
)
|
(
|
)
|
||||
Other Comprehensive Loss
|
||||||||
Foreign currency translation adjustments
|
( |
) | ||||||
Total Comprehensive Loss
|
$
|
(
|
)
|
$
|
(
|
)
|
||
Loss per Share:
|
||||||||
Basic and Diluted
|
$
|
(
|
)
|
$
|
(
|
)
|
||
Weighted average shares outstanding, basic and diluted
|
|
|
Three Months Ended March 31, 2023 |
||||||||||||||||||||||||||||||||
Preferred Stock
|
Common Stock
|
|||||||||||||||||||||||||||||||
Number of
|
Number of
|
Accumulated
|
||||||||||||||||||||||||||||||
Shares | Shares | Other | ||||||||||||||||||||||||||||||
Issued and
|
Issued and
|
Additional Paid-
|
Accumulated
|
Comprehensive
|
||||||||||||||||||||||||||||
Outstanding
|
Par Value
|
Outstanding |
Par Value
|
in Capital
|
Deficit
|
Loss | Total | |||||||||||||||||||||||||
Balances as of December 31, 2022
|
|
$
|
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||||||||||||||
Shares issued for services |
||||||||||||||||||||||||||||||||
Net loss
|
-
|
|
-
|
|
|
(
|
)
|
|
(
|
)
|
||||||||||||||||||||||
Foreign currency translation adjustment
|
- | - | ( |
) | ( |
) | ||||||||||||||||||||||||||
Balances as of March 31, 2023
|
|
$
|
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
Three Months Ended March 31, 2022 | ||||||||||||||||||||||||||||||||
Preferred Stock |
Common Stock | |||||||||||||||||||||||||||||||
Number of
|
Number of
|
Accumulated
|
||||||||||||||||||||||||||||||
Shares |
Shares | Other |
||||||||||||||||||||||||||||||
Issued and
|
Issued and
|
Additional Paid-
|
Accumulated
|
Comprehensive |
||||||||||||||||||||||||||||
Outstanding
|
Par Value |
Outstanding | Par Value |
in Capital
|
Deficit |
Loss | Total | |||||||||||||||||||||||||
Balances as of December 31, 2021
|
|
$
|
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||||||||||||||
Cashless warrant exercise
|
||||||||||||||||||||||||||||||||
Warrant exercise
|
||||||||||||||||||||||||||||||||
Shares issued in conjunction with Note Payable
|
||||||||||||||||||||||||||||||||
Net loss
|
-
|
|
-
|
|
|
(
|
)
|
|
(
|
)
|
||||||||||||||||||||||
Foreign currency translation adjustment
|
- | - | ||||||||||||||||||||||||||||||
Balances as of March 31, 2022
|
|
$
|
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
Three Months Ended March 31,
|
||||||||
2023
|
2022
|
|||||||
Cash Flows - Operating Acivities:
|
||||||||
Net loss
|
$
|
(
|
)
|
$
|
(
|
)
|
||
Adjustments to reconcile net loss to net cash used by operating activities
|
||||||||
Depreciation and Amortization
|
|
|
||||||
Bad debt expense
|
|
|
||||||
Change in fair value of derivative liabilities
|
(
|
)
|
||||||
Loss on issuance of debt
|
||||||||
Amortization of debt issuance costs and original issue discount
|
|
|
||||||
Accrued interest
|
|
|
||||||
Changes in operating assets and liabilities
|
||||||||
Accounts receivable - trade
|
|
|
||||||
Inventory
|
(
|
)
|
|
|||||
Prepaid expenses and other assets
|
|
|
||||||
Accounts payable
|
|
(
|
)
|
|||||
Accrued expenses
|
|
|
||||||
Contract liabilties
|
(
|
)
|
(
|
)
|
||||
Net Cash Used in Operating Activities
|
(
|
)
|
(
|
)
|
||||
Cash Flows - Investing Activities
|
||||||||
Proceeds from sale of property and equipment
|
|
|
||||||
Purchase of property and equipment
|
( |
) | ||||||
Net Cash Flows Provided by (Used in) Investing Activities
|
(
|
)
|
|
|||||
Cash Flows - Financing Activities
|
||||||||
Proceeds from senior promissory notes
|
||||||||
Payments
to factoring agent, net
|
( |
) | ( |
) | ||||
Proceeds from warrant exercises
|
|
|
||||||
Payments of principal on finance leases
|
(
|
)
|
(
|
)
|
||||
Net Cash Flows Provided by Financing Activities
|
(
|
)
|
|
|||||
Effect of Exchange Rates on Cash
|
(
|
)
|
(
|
)
|
||||
Net Change in Cash During Period
|
(
|
)
|
(
|
)
|
||||
Cash at Beginning of Period
|
|
|
||||||
Cash at End of Period
|
$
|
|
$
|
|
||||
Supplemental Information:
|
||||||||
Cash paid for interest
|
$
|
|
$
|
|
||||
Non-cash Investing and Financing Activities:
|
||||||||
Reclassification of warrant liability due to cashless warrant exercise
|
$
|
|
$
|
|
||||
Warrants issued in conjunction with senior secured promissory note payable
|
||||||||
Common shares issued in conjunction with senior secured promissory note payable
|
||||||||
Common shares issued for advisory shares
|
1.
|
Nature of the Business and Basis of Presentation
|
2. |
Going Concern
|
3. |
Summary of Significant Accounting Policies
|
4.
|
Loss per Share
|
Three Months Ended
|
||||||||
(in Thousands) |
March 31, 2023
|
March 31, 2022
|
||||||
Weighted average shares outstanding
|
||||||||
Common shares
|
|
|
||||||
Common shares issuable assuming exercise of nominally priced warrants
|
|
|
||||||
Weighted average shares outstanding
|
|
|
Three Months Ended | ||||||||
(in Thousands) |
March 31, 2023
|
March 31, 2022
|
||||||
Common stock options
|
|
|
||||||
Common stock purchase warrants
|
|
|
||||||
Convertible notes payable
|
|
|
||||||
|
|
5. |
Accrued Expenses
|
(in Thousands)
|
March 31, 2023
|
December 31, 2022
|
||||||
Registration penalties
|
$
|
|
$
|
|
||||
License fees
|
|
|
||||||
Director and professional fees |
|
|
||||||
Employee compensation |
||||||||
Other
|
|
|
||||||
|
$
|
|
$
|
|
6. |
Senior Secured Debt, In Default
|
March 31, 2023
|
December 31, 2022
|
|||||||||||||||||||||||
(in thousands)
|
Principal
|
Debt Discount
|
Carrying Value
|
Principal
|
Debt Discount
|
Carrying Value
|
||||||||||||||||||
Senior secured debt
|
$
|
|
$
|
(
|
)
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
7. |
Convertible Promissory Notes Payable
|
|
As of March 31, 2023
|
|||||||||||||||||||
(In thousands, except conversion price)
|
Conversion
Price
|
Principal
|
Remaining
Debt Discount
|
Remaining
Embedded
Conversion
Option
|
Carrying Value
|
|||||||||||||||
Acquisition convertible promissory note, in default
|
$
|
|
|
|
|
|
||||||||||||||
Convertible promissory notes payable, related parties, in default
|
$
|
|
|
|
|
|
||||||||||||||
2022 convertible notes payable
|
$
|
|
|
(
|
)
|
|
|
|||||||||||||
2022 convertible notes payable, related parties
|
$
|
|
|
(
|
)
|
|
|
|||||||||||||
Total Convertible Promissory Notes Payable
|
$
|
|
$
|
(
|
)
|
$
|
|
$
|
|
|
As of December 31, 2022
|
|||||||||||||||||||
(In thousands, except conversion price)
|
Conversion
Price
|
Principal
|
Remaining
Debt
Discount
|
Remaining
Embedded
Conversion
Option
|
Carrying
Value
|
|||||||||||||||
Acquisition convertible promissory note, in default
|
$
|
|
|
|
|
|
||||||||||||||
Convertible promissory note, related party, in default
|
$
|
|
|
|
|
|
||||||||||||||
2022 convertible notes payable
|
$
|
|
|
(
|
)
|
|
|
|||||||||||||
2022 convertible notes payable, related parties
|
$
|
|
|
(
|
)
|
|
|
|||||||||||||
Total Convertible Promissory Notes
|
$
|
|
$
|
(
|
)
|
$
|
|
$
|
|
8. |
Fair Value Measurements
|
Fair value measured at March 31,
2023
|
||||||||||||||||
Quoted prices in
|
Significant other
|
Significant
|
||||||||||||||
Fair value at
|
active markets
|
observable inputs
|
unobservable inputs
|
|||||||||||||
(in thousands) |
March 31, 2023
|
(Level 1)
|
(Level 2)
|
(Level 3)
|
||||||||||||
Warrant liability
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
Embedded conversion option
|
|
|
|
|
||||||||||||
Total fair value
|
$ |
|
$ |
|
$ |
|
$ |
|
Fair value measured at December 31, 2022
|
||||||||||||||||
Quoted prices in | Significant other | Significant | ||||||||||||||
Fair value at | active markets | observable inputs |
unobservable inputs
|
|||||||||||||
(in thousands) |
December 31, 2022
|
(Level 1)
|
(Level 2)
|
(Level 3)
|
||||||||||||
Warrant liability
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
Embedded conversion option
|
|
|
|
|
||||||||||||
Total fair value
|
$
|
|
$
|
|
$
|
|
$
|
|
March 31, | December 31, |
|||||||
2023 |
2022
|
|||||||
Weighted average remaining life in years
|
|
|
||||||
Weighted average volatility
|
|
%
|
|
%
|
||||
Value of underlying shares
|
$ | $ | ||||||
Weighted average risk free interest rate
|
|
%
|
|
%
|
||||
Expected dividend yield
|
|
%
|
|
%
|
Warrants
|
Fair Value
|
Fair Value
|
||||||||||
(in thousands, except per share data)
|
Outstanding
|
per Share
|
(in thousands)
|
|||||||||
Balance at December 31, 2022
|
|
$
|
|
$
|
|
|||||||
Loss on remeasurement of warrant liability
|
|
|
||||||||||
Balance at March 31, 2023
|
|
$
|
|
$
|
|
March 31, 2023
|
December 31, 2022
|
|||||||
|
||||||||
Conversion Price(1)
|
$
|
|
$
|
|
||||
Value of underlying shares
|
$
|
|
$
|
|
||||
Interest Rate (annual) (2)
|
|
%
|
|
%
|
||||
Volatility (annual) (3)
|
|
%
|
|
%
|
||||
Time to Maturity (Years)
|
|
|
(1) |
|
(2) |
|
(3) |
|
(in thousands)
|
Conversion
Liability
|
|||
Balance December 31, 2022
|
$
|
|
||
Change in fair value
|
(
|
)
|
||
Balance March 31, 2023
|
$
|
|
9. |
Revenue
|
Three Months Ended March 31, 2023
|
Three Months Ended March 31, 2022
|
|||||||||||||||||||||||
United States
|
International
|
Total
|
United States
|
International
|
Total
|
|||||||||||||||||||
Accessory and parts revenue
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
|||||||||||
System revenue
|
|
|
|
|
|
|
||||||||||||||||||
License fees and other
|
|
|
|
|
|
|
||||||||||||||||||
Product Revenue
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||||
Rental Income
|
|
|
|
|
|
|
||||||||||||||||||
Total Revenue
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
10. |
Concentration of Credit Risk and Limited Suppliers
|
Three Months Ended
|
||||||||
March 31, 2023
|
March 31, 2022
|
|||||||
Purchases:
|
||||||||
Vendor A
|
|
%
|
|
%
|
11. |
Commitments and Contingencies
|
12. |
Subsequent Events
|
Item 2. |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
|
For the Three Months Ended
|
||||||||||||||||
March 31,
|
Change
|
|||||||||||||||
2023
|
2022
|
$
|
%
|
|||||||||||||
Revenues:
|
||||||||||||||||
Total Revenue
|
$
|
3,775
|
$
|
3,195
|
$
|
580
|
18
|
%
|
||||||||
Cost of Revenues
|
1,262
|
889
|
373
|
42
|
%
|
|||||||||||
Gross Margin
|
2,513
|
2,306
|
207
|
9
|
%
|
|||||||||||
Operating Expenses:
|
||||||||||||||||
General and administrative
|
2,759
|
2,205
|
554
|
25
|
%
|
|||||||||||
Selling and marketing
|
1,412
|
1,715
|
(303
|
)
|
-18
|
%
|
||||||||||
Research and development
|
131
|
166
|
(35
|
)
|
-21
|
%
|
||||||||||
Depreciation and amortization
|
189
|
176
|
13
|
7
|
%
|
|||||||||||
Operating Loss
|
(1,978
|
)
|
(1,956
|
)
|
(22
|
)
|
1
|
%
|
||||||||
Other Income (Expense), net
|
(11,102
|
)
|
(3,145
|
)
|
(7,957
|
)
|
253
|
%
|
||||||||
Net Loss
|
$
|
(13,080
|
)
|
$
|
(5,101
|
)
|
(7,979
|
)
|
156
|
%
|
For the three months ended March 31,
|
Change
|
|||||||||||||||
2023
|
2022
|
$ |
|
%
|
||||||||||||
Interest expense
|
$
|
(4,278
|
)
|
$
|
(3,192
|
)
|
$
|
(1,086
|
)
|
34
|
%
|
|||||
Change in fair value of derivatives
|
(6,797
|
)
|
3,482
|
(10,279
|
)
|
-295
|
%
|
|||||||||
Loss on issuance of debt
|
-
|
(3,434
|
)
|
3,434
|
nm
|
|||||||||||
Other expense
|
(27
|
)
|
-
|
(27
|
)
|
nm
|
||||||||||
Loss on foreign currency exchange
|
-
|
(1
|
)
|
1
|
nm
|
|||||||||||
Other expense, net
|
$
|
(11,102
|
)
|
$
|
(3,145
|
)
|
$
|
(7,957
|
)
|
253
|
%
|
For the three months ended March 31,
|
||||||||
(in Thousands)
|
2023
|
2022
|
||||||
Cash flows used by operating activities
|
$
|
(371
|
)
|
$
|
(3,132
|
)
|
||
Cash flows (used by) provided by investing activities
|
$
|
(18
|
)
|
$
|
360
|
|||
Cash flows (used by) provided by financing activities
|
$
|
(654
|
)
|
$
|
2,470
|
Item 4. |
CONTROLS AND PROCEDURES
|
1.
|
Expertise and resources to analyze and properly apply U.S. GAAP to complex and non-routine transactions such as complex financial instruments and derivatives and complex sales distributing
agreements with select vendors.
|
2.
|
A lack of internal resources to analyze and properly apply U.S. GAAP to accounting for financial instruments included in service agreements with select vendors.
|
3.
|
The Company has failed to design and implement controls around all accounting and IT processes and procedures and, as such, we believe that all its accounting and IT processes and procedures
need to be re-designed and tested for operating effectiveness.
|
Item 1. |
LEGAL PROCEEDINGS.
|
Item 1A. |
RISK FACTORS.
|
Item 2. |
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.
|
Item 3. |
DEFAULTS UPON SENIOR SECURITIES.
|
Item 4. |
MINE SAFETY DISCLOSURES.
|
Item 5. |
OTHER INFORMATION.
|
Item 6. |
EXHIBITS
|
Exhibit No.
|
Description
|
|
|
Articles of Incorporation (Incorporated by reference to Exhibit 3.1 to the Form 10-SB filed with the SEC on December 18, 2007).
|
|
Certificate of Amendment to the Articles of Incorporation (Incorporated by reference to Appendix A to the Definitive Schedule 14C filed with the SEC on October 16, 2009).
|
|
Certificate of Amendment to the Articles of Incorporation (Incorporated by reference to Exhibit A to the Definitive Schedule 14C filed with the SEC on April 16, 2012).
|
|
Bylaws (Incorporated by reference to Exhibit 3.02 to the Form 10-SB filed with the SEC on December 18, 2007).
|
|
Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock of the Company dated March 14, 2014 (Incorporated by reference to Exhibit 3.1 to the Form 8-K filed
with the SEC on March 18, 2014).
|
|
Certificate of Amendment to the Articles of Incorporation, dated September 8, 2015 (Incorporated by reference to Exhibit 3.6 to the Form 10-K filed with the SEC on March 30, 2016).
|
|
Preferred Stock of the Company dated January 12, 2016 (Incorporated by reference to Exhibit 3.1 to the Form 8-K filed with the SEC on January 19, 2016).
|
|
Preferred Stock of the Company dated January 31, 2020 (Incorporated by reference to Exhibit 3.1 to the Form 8-K filed with the SEC on February 6, 2020).
|
Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock of the Company dated January 31, 2020 (Incorporated by reference to Exhibit 3.1 to the Form 8-K filed
with the SEC on February 6, 2020).
|
|
Certificate of Designation of Series D Convertible Preferred Stock (Incorporated by reference to Exhibit 3.1 to the Form 8-K filed with the SEC on May 20, 2020).
|
|
Certificate of Amendment of the Articles of Incorporation (Incorporated by reference to Exhibit 3.1 to the Form 8-K filed with the SEC on January 5, 2021).
|
|
Certificate of Amendment of the Articles of Incorporation, dated January 31, 2023 (Incorporated by reference to Exhibit 3.12 to the Form S-1/A filed with the SEC on January 31, 2023).
|
|
Rule 13a-14(a)/15d-14(a) Certification of the Chief Executive Officer.
|
|
|
|
Rule 13a-14(a)/15d-14(a) Certification of the Chief Financial Officer.
|
|
|
|
Section 1350 Certification of the Principal Executive Officer.
|
|
|
|
Section 1350 Certification of the Chief Financial Officer.
|
|
|
|
101.INS*
|
XBRL Instance.
|
|
|
101.SCH*
|
XBRL Taxonomy Extension Schema.
|
|
|
101.CAL*
|
XBRL Taxonomy Extension Calculation.
|
|
|
101.DEF*
|
XBRL Taxonomy Extension Definition.
|
|
|
101.LAB*
|
XBRL Taxonomy Extension Labels.
|
|
|
101.PRE*
|
XBRL Taxonomy Extension Presentation.
|
|
|
104
|
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
|
|
SANUWAVE HEALTH, INC.
|
|
|
|
|
Dated: May 11, 2023
|
By: /s/ Kevin A. Richardson, II
|
|
|
|
Kevin A. Richardson, II
|
|
|
Chief Executive Officer
|
(Duly Authorized Officer and Principal Executive Officer)
|
||
Dated: May 11, 2023
|
By: /s/ Toni Rinow
|
|
|
|
Toni Rinow
|
|
|
Chief Financial Officer
|
(Principal Financial and Accounting Officer)
|